42,735 Shares in PROCEPT BioRobotics Corporation $PRCT Purchased by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 42,735 shares of the company’s stock, valued at approximately $2,462,000. Kornitzer Capital Management Inc. KS owned approximately 0.08% of PROCEPT BioRobotics at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. ANTIPODES PARTNERS Ltd purchased a new stake in shares of PROCEPT BioRobotics in the 1st quarter worth approximately $30,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in PROCEPT BioRobotics during the first quarter worth $40,000. CWM LLC boosted its position in PROCEPT BioRobotics by 69.5% during the 1st quarter. CWM LLC now owns 873 shares of the company’s stock valued at $51,000 after acquiring an additional 358 shares in the last quarter. AlphaQuest LLC increased its holdings in shares of PROCEPT BioRobotics by 1,262.5% in the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock valued at $63,000 after acquiring an additional 1,010 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in shares of PROCEPT BioRobotics by 32.5% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock worth $64,000 after acquiring an additional 270 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Trading Up 1.1%

Shares of PROCEPT BioRobotics stock opened at $34.99 on Monday. The firm’s 50 day simple moving average is $37.21 and its two-hundred day simple moving average is $48.93. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -22.57 and a beta of 0.99. PROCEPT BioRobotics Corporation has a 12-month low of $32.11 and a 12-month high of $103.81. The company has a current ratio of 9.21, a quick ratio of 7.86 and a debt-to-equity ratio of 0.13.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.06. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. The business had revenue of $79.18 million during the quarter, compared to the consensus estimate of $75.67 million. During the same period in the previous year, the firm posted ($0.50) earnings per share. The business’s revenue for the quarter was up 48.3% compared to the same quarter last year. Analysts predict that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Piper Sandler dropped their price objective on PROCEPT BioRobotics from $80.00 to $55.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. Wells Fargo & Company cut their price objective on shares of PROCEPT BioRobotics from $75.00 to $58.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. Morgan Stanley lowered their target price on shares of PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating for the company in a research note on Tuesday, July 15th. Oppenheimer raised PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research report on Tuesday, September 2nd. Finally, BTIG Research reissued a “neutral” rating on shares of PROCEPT BioRobotics in a research report on Tuesday, September 16th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $67.50.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).